Tisagenlecleucel, sold as Kymriah, has gained its second indication following the FDA's approval of the chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
The FDA has approved Novartis' chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
The indication includes diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma after 2 or more lines of systemic therapy. For patients who do not respond to initial therapy, limited treatment options are available that provide durable response, and median life expectancy is approximately 6 months.
The approval marks tisagenlecleucel's second indication. In August 2017, the therapy became the first CAR T-cell therapy approved for the treatment of B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients.
“The goal of Kymriah is to provide physicians with a therapy that has demonstrated durable response rates in relapsed or refractory DLBCL patients, a patient population that has endured multiple rounds of chemotherapy with many having experienced unsuccessful stem cell transplants,” said Stephen J. Schuster, MD, Robert and Margarita Louis-Dreyfus professor in chronic lymphocytic leukemia and lymphoma clinical care and research in Penn’s Perelman School of Medicine and director of the Lymphoma Program at the Abramson Cancer Center. “With this approval, physicians now have a meaningful therapeutic options that can achieve and maintain a sustained response without stem cell transplant along with a consistent safety profile.”
The approval follows results of the pivotal phase 2 JULIET study, which enrolled patients with r/r DLBCL from 27 sites in 10 countries. Patients showed progression of disease after receiving at least 2 lines of chemotherapy and were ineligible or failed autologous stem cell transplant. Tisagenlecleucel showed an overall response rate of 50% (95% CI, 38%-62%), with 32% of patients achieving a complete response and 18% of patients achieving a partial response. The median duration of response had not been reached.
The therapy will compete with Gilead Science’s CAR T-cell therapy axicabtagene ciloleucel (Yescarta), which was approved in October 2017 for adult patients with B-cell lymphoma.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More